Bitte aktiviere Javascript und schalte etwaige Werbeblocker ab

Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: Aurubis AG: Enabling tomorrow: Aurubis releases new Sustainability Report

EQS-News: Aurubis AG: Enabling tomorrow: Aurubis releases new Sustainability Report

0

EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24051/375px-PLAN._BUILT._PERFORM..png

EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.

EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.

0

EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24051/375px-PLAN._BUILT._PERFORM..png

EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.

EQS-News: CANCOM: Financial year 2022 ends with record revenue in the fourth quarter. Dividend proposal of €1.00 per share and forecast 2023 published.

0

EQS-News: SHOP APOTHEKE EUROPE and GALENICA enter into a strategic partnership and jointly establish the leading online pharmacy in Switzerland.: https://upload.wikimedia.org/wikipedia/commons/thumb/0/07/Shop_Apotheke_Europe_logo.svg/640px-Shop_Apotheke_Europe_logo.svg.png

EQS-News: SHOP APOTHEKE EUROPE and GALENICA enter into a strategic partnership and jointly establish the leading online pharmacy in Switzerland.

EQS-News: SHOP APOTHEKE EUROPE and GALENICA enter into a strategic partnership and jointly establish the leading online pharmacy in Switzerland.

0

EQS-Adhoc: SHOP APOTHEKE EUROPE N.V. and GALENICA AG enter into strategic partnership and establish a joint venture for the Swiss business; execution of capital increase.: https://upload.wikimedia.org/wikipedia/commons/thumb/0/07/Shop_Apotheke_Europe_logo.svg/640px-Shop_Apotheke_Europe_logo.svg.png

EQS-Adhoc: SHOP APOTHEKE EUROPE N.V. and GALENICA AG enter into strategic partnership and establish a joint venture for the Swiss business; execution of capital increase.

EQS-Adhoc: SHOP APOTHEKE EUROPE N.V. and GALENICA AG enter into strategic partnership and establish a joint venture for the Swiss business; execution of capital increase.

0

EQS-Adhoc: United Internet with successful fiscal year 2022 : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24075/330px-UnitedInternet_logo.svg.png

EQS-Adhoc: United Internet with successful fiscal year 2022

EQS-Adhoc: United Internet with successful fiscal year 2022

0

EQS-Adhoc: United Internet with successful fiscal year 2022 : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24075/330px-UnitedInternet_logo.svg.png

EQS-Adhoc: United Internet with successful fiscal year 2022

EQS-Adhoc: United Internet with successful fiscal year 2022

0

EQS-Adhoc: 1&1 with successful fiscal year 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24057/Drillisch_AG_Logo.svg.png

EQS-Adhoc: 1&1 with successful fiscal year 2022

EQS-Adhoc: 1&1 with successful fiscal year 2022

0

EQS-Adhoc: 1&1 with successful fiscal year 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24057/Drillisch_AG_Logo.svg.png

EQS-Adhoc: 1&1 with successful fiscal year 2022

EQS-Adhoc: 1&1 with successful fiscal year 2022

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership

EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership

0

EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership

EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership

0

EQS-News: Rational AG fiscal year 2022: sales revenues grow by 31 percent to break the one billion euro mark for the first time – significant increase in EBIT margin to 23.2 percent: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24119/375px-Rational_AG_Logo.svg.png

EQS-News: Rational AG fiscal year 2022: sales revenues grow by 31 percent to break the one billion euro mark for the first time – significant increase in EBIT margin to 23.2 percent

EQS-News: Rational AG fiscal year 2022: sales revenues grow by 31 percent to break the one billion euro mark for the first time – significant increase in EBIT margin to 23.2 percent

0

EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year

EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

EQS-News: KION Group and Li-Cycle Agree to Form Strategic Battery Recycling Partnership Focused on Circular Economy: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23724/Kion_Group_logo.svg.png

EQS-News: KION Group and Li-Cycle Agree to Form Strategic Battery Recycling Partnership Focused on Circular Economy

EQS-News: KION Group and Li-Cycle Agree to Form Strategic Battery Recycling Partnership Focused on Circular Economy

0

EQS-Adhoc: VARTA AG: VARTA AG reaches agreement with banks on comprehensive restructuring concept

EQS-Adhoc: VARTA AG: VARTA AG reaches agreement with banks on comprehensive restructuring concept

0

EQS-Adhoc: VARTA AG: VARTA AG reaches agreement with banks on comprehensive restructuring concept

EQS-Adhoc: VARTA AG: VARTA AG reaches agreement with banks on comprehensive restructuring concept

0

EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)

EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)

0

EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)

EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)

0

EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24058/375px-Freenet_AG_Logo.svg.png

EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance

EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance

0

EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24058/375px-Freenet_AG_Logo.svg.png

EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance

EQS-News: freenet confirms 2022 preliminary results, dividend proposal of 1.68 euros and 2023 guidance

0

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc

0

EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis

EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis

0